| | miRNA | | Target gene | Cellular function | Ovarian cancer cell line | Reference |
| |
miR-200 family | miR-141 | KEEP1 | Cisplatin resistance | A2780 (EOC), TOV112D (EAC), TOV21G (CAC) | [61] | | miR-141, miR-200a | MAPK14 | Oxidative stress response, pactitaxel sensitivity | SKOV3 (EOC) | [55] | | miR-200a | ZEB2 | EMT, stemness, migration, invasion | OVCAR3 (EOC) | [56] | | miR-200c | ZEB1, TUBB3 | EMT, stemness, adhesion, migration, invasion, paclitaxel sensitivity | HEY (SAC), SKOV3 (EOC) | [57, 59, 60] | | miR-200a, miR-200b | IL8, CXCL1 | Angiogenesis | HeyA8 (SAC), ES2 (CAC) | [58] |
| |
miR-199/214 cluster | miR-199a-5p | IKKB, HIF-1A, HIF-2A | Inflammation, chemosensitivity, migration, metastasis | A2780 (EOC), R454 (EOC), 01-28 (EOC), R182 (EOC), 01-19B (EOC), R1185 (EOC), primary culture | [62, 63, 67] | | miR-199a-3p | CD44 | Stemness, chemosensitivity | primary culture | [64] | | miR-199b-5p | JAG1 | Cisplatin sensitivity | A2780 (EOC), OV119 (EOC) | [65] | | miR-214 | PTEN, CCL5 | Proliferation, cell survival, cisplatin resistance, CAFs activity | A2780 (EOC), HeyA8 (SAC), SKOV3ip1 (EOC), OV119 (EOC), primary culture | [63, 66, 87] |
| | let-7 | | HMGA2 | Carcinogenesis | A2780 (EOC), HeyA8 (SAC), IGROV-1 (EOC) | [69, 70] |
| |
miR-506 | | SNAI2 | EMT | HeyA8 (SAC), SKOV3 (EOC), OVCA420 (EOC), OVCA433 (EOC) | [26] | | | CDK4, CDK6 | Proliferation, senescence | HeyA8 (SAC), SKOV3 (EOC), OVCA432 (EOC), OVCA433 (EOC) | [73] |
| | miR-92a | | ITGA5 | Adhesion, invasion, proliferation | A2780 (EOC), SKOV3ip1 (EOC), OVISE (CAC) | [74] |
| |
miR-31 | | MET | Paclitaxel sensitivity | KFr13 (EOC) | [76] | | | CEBPA, STK40, E2F2 | Proliferation | SKOV3 (EOC), OVCAR8 (EOC), OVCA433 (EOC) | [77] |
| | miR-484 | | VEGFB, VEGFR2 | Angiogenesis | SKOV3 (EOC), MDAH-2274 (EOC) | [78] |
| | miR-502d-3p | | EPHA2, EPHB2 | Proliferation, migration, invasion | HeyA8 (SAC), SKOV3ip1 (EOC), ES2 (CAC) | [79] |
| | miR-155 | | SATB1, CD200 | DCs activity | ID8 (EOC, mouse) | [90] |
|
|
